



Published in final edited form as:

Clin Perinatol. 2014 December ; 41(4): 877–894. doi:10.1016/j.clp.2014.08.009.

It's Not Your Mother's Marijuana: Effects on Maternal-Fetal Health and the Developing Child

Tamara D. Warner, PhD¹, Dikea Roussos-Ross, MD², and Marylou Behnke, MD¹

Tamara D. Warner: warnertd@peds.ufl.edu; Dikea Roussos-Ross: kroussos@ufl.edu; Marylou Behnke: behnkem@peds.ufl.edu

¹University of Florida, Department of Pediatrics, P.O. Box 100296, Gainesville, FL 32610-0296, (352) 273-8985

²University of Florida, Department of Obstetrics and Gynecology, P.O. Box 100294, Gainesville, FL 32610-0294, (352) 273-7660

SYNOPSIS

Pro-marijuana advocacy efforts exemplified by the “medical” marijuana movement, coupled with the absence of conspicuous public health messages about the potential dangers of marijuana use during pregnancy, could lead to greater use of today’s more potent marijuana, which could have significant short- and long-term consequences. This article will review the current literature regarding the effects of prenatal marijuana use on the pregnant woman and her offspring.

Keywords

Pregnancy; marijuana; cannabis; prenatal exposure; substance use; perinatal outcomes; fetal effects; developmental effects

INTRODUCTION

Societal attitudes towards marijuana use in the United States are undergoing an historical shift. In the 1960s, a generation of young people embraced marijuana for personal recreational use. Today, “medical” marijuana (*cannabis sativa*) has been approved for use in 22 states and the District of Columbia either by legislation or by popular vote in statewide referenda or ballot initiatives; 15 of the 22 legal actions were passed in the last decade (since 2004).¹ As of May, 2014, another seven states have pending legislation or ballot measures to legalize medical marijuana.² In addition, two states, Colorado and Washington state, have legalized marijuana for *recreational* use. The attitudinal shift is apparent not just among

© 2014 Elsevier Inc. All rights reserved.

CORRESPONDING AUTHOR: Tamara D. Warner, Ph.D., Department of Pediatrics, P.O. Box 100296, Gainesville, FL 32610-0296, warnertd@peds.ufl.edu.

The authors have no conflicts of interest or affiliations with companies that have direct financial interests in the subject matter of this article.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

adults but among teens as well. The most recent annual survey of adolescent drug use indicates that the annual prevalence of marijuana use has been trending upward since 2008 for 8th, 10th, and 12th graders; perhaps more importantly, the perceived risk of regular marijuana use has declined sharply in recent years, a trend that started in 2005.³

Epidemiology of Marijuana Use Among Pregnant Women

Marijuana is the most commonly used illicit drug during pregnancy. Table 1 shows the 2011–2012 combined annual prevalence rates based on past-month use for illicit drugs, alcohol, and cigarettes by pregnant women in the U.S.⁴ The rate for marijuana and hashish was 5.2%, which translates to 115,000 pregnant women using marijuana annually. Still, the prevalence rates for marijuana are significantly lower than the rates for alcohol (8.5%) and cigarette (15.9%) use during pregnancy. Table 1 also shows the prevalence rates by age and trimester for marijuana, cigarette and alcohol use by pregnant women. Young adolescents (ages 15 to 17) have the highest rate of marijuana use during pregnancy (16.5%), which is more than double the rate for 18- to 25-year olds (7.5%).⁴ Marijuana use during pregnancy is highest during the 1st trimester (10.7%), then declines significantly during the 2nd trimester (2.8%) and 3rd trimester (2.3%).⁴ Following childbirth, marijuana use rebounds quickly.⁵ Box 1 outlines some of the socio-demographic characteristics that are common among women who use illicit drugs during pregnancy and some that may be unique to women who use marijuana during pregnancy.⁶

Box 1

Socio-Demographic Characteristics of Illicit Drug-Using Pregnant Women

Common Among Women Who Use Illicit Drugs During Pregnancy

- Pre-pregnancy Body Mass Index scores in the underweight range
- Folic acid supplementation lacking in the periconceptual period
- Alcohol use and cigarette smoking during pregnancy
- Partners are illicit drug users
- Intimate partner violence
- Lower levels of education and income
- Higher rates of unemployment

May Be Unique to Women Who Use Marijuana During Pregnancy*

- Excessive weight gain during pregnancy
- More likely to be nulliparous
- More likely to have had an induced abortion in the past

* Data is from a population-based study using the National Birth Defects Prevention Study with a relatively small sample of marijuana users (N = 189)

Potential Impact of Medical Marijuana

The legal status of medical marijuana is under debate. Marijuana is a Schedule I drug under the Controlled Substance Act, a federal law which preempts actions taken by individual

states to legalize its use, cultivation and distribution.⁷ Legal scholars have argued that when used for medicinal purposes, marijuana should be considered a pharmaceutical agent governed by the Food, Drug and Cosmetic Act with regulatory oversight, including evaluation of its safety and efficacy, provided by the Food and Drug Administration.⁷

There is emerging evidence that states with legalized medical marijuana have higher rates of marijuana use, depending on specific aspects of laws and policies.⁸ In states that allow home cultivation and legal dispensaries, higher levels of recreational use and higher levels of heavy use are found. By contrast, states that restrict broad access to medical marijuana by requiring annual registration of patients have lower prevalence rates and treatment admissions compared to those that do not.⁹

Growing pro-marijuana advocacy efforts may increase marijuana use among pregnant women. In the absence of public health messages about the potential risks, marijuana may be perceived as “safe” to use during pregnancy compared to other illicit drugs and in comparison to alcohol and cigarettes. Medical marijuana laws that involve the use of dispensaries have been shown to drive down prices,^{10,11} which will likely increase use among certain groups.⁹ In a recent study, urban, low-income, primarily African-American postpartum women reported perceptions of relatively lower risk of marijuana compared to licit drugs as well as roughly equivalent costs of marijuana and cigarettes.¹²

Increasing Potency and Consumption of Marijuana

The potency of marijuana has increased markedly during the past 40 years in the U.S., and elsewhere (review by McLaren et al., 2008).¹³ From the 1970s to the 2000s, there has been an estimated 6- to 7-fold increase in the potency of cannabis seized in the U.S. as measured by the percentage of Δ^9 -tetrahydrocannabinol (THC), the most psychoactive of the 70 cannabinoids found in cannabis.¹⁴ In the 15-year period between 1993 and 2008, the mean concentration of THC rose from 3.4% to 8.8%.¹⁵

In addition to concerns about potency, the amount of marijuana consumed, on average, appears to be increasing among younger adults, particularly minorities due to the growing popularity of blunts (marijuana-filled cigars) compared to joints and pipes. One study found that blunts contain significantly greater amounts of marijuana – up to 1.5 times more than joints and 2.5 times more than pipes.¹⁶

ISSUES RELATED TO MARIJUANA USE DURING PREGNANCY

Screening Pregnant Women for Marijuana Use

Box 2 summarizes some of the recommendations made by the American College of Obstetrics and Gynecology (ACOG)^{17–19} and the American Society of Addiction Medicine (ASAM)²⁰ related to drug use during pregnancy. ACOG recommends that screening for substance abuse be part of complete obstetric care and be performed routinely throughout pregnancy as women may be more willing to disclose substance abuse as they develop rapport with their provider.¹⁹ Additionally, it is recommended that providers become knowledgeable on brief intervention techniques and referral services for treatment. ASAM

also advocates universal screening for drug use among pregnant women and appropriate referral for substance treatment when patients who require services are identified.²⁰

Box 2

Professional Organizations' Recommendations Related to Drug Use During Pregnancy

American College of Obstetrics and Gynecology (ACOG)¹

- Universal screening for drug use in females of reproductive age
- Screening at the first prenatal or intake visit and at least once per trimester thereafter
- Consider drug testing (with patient consent) when screening tests are positive
- Refer for substance abuse treatment for all pregnant women who have evidence of drug use in pregnancy
- Protect the physician-patient relationship

American Society of Addiction Medicine (ASAM)²

- Prenatal education about all drugs for all pregnant women
- Universal screening to identify "at risk" women including repeated follow up assessments
- Culturally competent public prevention programs to educate the public about realistic dangers of drug use in pregnancy
- Education of health care providers in the care and management of women with evidence of drug use before, during, and after pregnancy
- Women who are pregnant should receive priority admission to substance treatment facilities

Data from ProCon.org. 22 legal medical marijuana states and dc: laws, fees, and possession limits - I Summary chart. Available at: <http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881>. Accessed May 30, 2014 and ProCon.org. 4 states with pending legislation to legalize medical marijuana (as of May 29, 2014). Available at: <http://medicalmarijuana.procon.org/view.resource.php?resourceID=002481>. Accessed May 30, 2014.

Screening should be performed with the consent of the pregnant woman and can be conducted with standardized questionnaires such as the 4 P's or the CRAFFT Interview¹⁸ (CRAFFT is available for download in 13 languages at <http://www.ceasarboston.org/CRAFFT/screenCRAFFT.php>). Another evidence-based and readily available screening tool is the 5 P's,²¹ an adaptation of the 4 P's which includes a question about peers (friends); an "integrated" version also asks about intimate partner violence, emotional health (worry, anxiety, depression or sadness), and cigarette use.²² Drug testing can be performed with the woman's permission. The three most commonly used specimens to establish drug use during the prenatal and perinatal periods are urine, meconium, and hair.²³ Of these, urine is used most frequently due to the ease of collection.²³ In regular marijuana users, urine testing can be positive up to 10 days after use; for chronic or heavy users, urine can be positive for up to 30 days after last use. Meconium is easily collected in the newborn nursery. It reveals exposure to marijuana in the 2nd and 3rd trimesters as this is when meconium is formed in the fetus.²³ Hair sampling has not been found to be as useful for detection of marijuana.

When considering drug testing in pregnancy, it is important for the clinician to be familiar with the reporting laws of the state in which he/she practices. States vary about whether

evidence of drug exposure to a fetus or newborn mandates reporting the case to the child welfare system with possible removal of children and/or incarceration of the mother.¹⁸ As of May 2014, there are 17 states that consider substance abuse during pregnancy to be child abuse under civil child-welfare statutes; 3 states consider it grounds for involuntary commitment to a mental health or substance abuse treatment facility (See Table 2).²⁴ These laws have been found to hinder the physician-patient relationship, decrease compliance with prenatal care, and increase the risk of perinatal mortality.^{17,18,25} Due to fears of incarceration or the loss of one's children, pregnant women may not be willing to disclose their use. For this reason, it is imperative to preserve the physician-patient relationship which will allow women to feel safer discussing drug use with their provider. Pregnant women who are identified as using drugs should be counseled and referred for substance abuse treatment. Early detection of drug use allows for timely implementation of harm reduction strategies during pregnancy.²⁶

Aside from the legal implications, there are additional barriers that obstetricians face when deciding whether to screen and/or test patients for substance use. Two such barriers are concerns about having the time to screen patients appropriately and a lack of local substance use treatment resources, particularly for pregnant women. The time barrier could be reduced if reimbursement was provided to physicians for screening pregnant patients for substance use, similar to the reimbursement for tobacco use screening. Local substance abuse treatment facilities can be located through the on-line Behavioral Health Treatment Services Locator, available from the Substance Abuse and Mental Health Services Administration (SAMHSA) at <http://findtreatment.samhsa.gov/locator/home>.

Effects of Prenatal Marijuana Use

A list of the possible pregnancy-related effects of prenatal marijuana use can be found in Box 3. Marijuana easily passes through the maternal circulation, into the placenta, and then fetus. It is also found in breast milk. Marijuana can be detected in umbilical cord blood, neonatal urine, and meconium.

Box 3

Possible Pregnancy-Related Effects of Prenatal Marijuana Use

- Decreased male fertility
- Decreased ovulation
- Altered hormones (prolactin, FSH, LH, estrogen)
- Altered oviductal transport, embryo implantation, maintenance of pregnancy
- Altered placental blood flow
- Intrauterine growth restriction
- Decreased gestational age
- Decreased birth weight

Pre-clinical studies are important as they can: (1) provide a level of control for confounding variables not achievable in clinical studies, (2) offer a framework for developing hypotheses

for further study in human populations, and (3) help to identify the pathologic changes that underlie the medical and behavioral changes observed in clinical studies. A full discussion of the pre-clinical literature is beyond the scope of this review and the reader is referred to pertinent studies and reviews available in the extant literature.²⁷⁻³⁰

Research into the effects of THC in humans began in the late 1800s with two major advances occurring when the main psychoactive compound in marijuana, THC, was identified by Gaoni and Mechoulam in 1964³¹ and when the existence of cannabinoid receptors, called the endocannabinoid system, was confirmed by DeVane et al in 1988.³²

Cannabinoid receptors are found in various tissues throughout the human body, including the brain and uterine decidua. Thus the physiologic functions of the endocannabinoid system are important to both early embryonic development and synaptic brain plasticity. However, exposure to exogenous cannabinoids could result in pathophysiologic changes secondary to the longer binding of THC to the receptors as compared to naturally occurring endocannabinoids.

With regard to early embryonic development, it is possible that exogenous cannabinoids could significantly disrupt regulation of blastocyst maturation, oviductal transport, implantation, and pregnancy maintenance. In addition, THC acts as an *in vivo* weak competitor of the estrogen receptor, producing a primary estrogen effect in male and female rats,³³ stifles trophoblast cell proliferation, and inhibits successful placentation, possibly producing other pregnancy related complications.^{34,35}

In the brain, cannabinoids alter executive functions in the pre-frontal cortex, including working memory, attention, and cognitive flexibility. Additionally, the release of neurotransmitters such as dopamine, serotonin, and acetylcholine, each of which affects cognitive functions in the prefrontal cortex, as well as behavior and mood, has been shown to be altered in the face of cannabinoid exposure.

Marijuana and Infertility

Human studies on male subjects have shown disruptions in the hypothalamic-pituitary-testicular axis with decreased lutenizing hormone, decreased testosterone, oligospermia and decreased sperm motility, thus possibly affecting male infertility.³⁶ Likewise, in women, chronic marijuana exposure has been associated with suppressed ovulation, altered prolactin, follicle-stimulating hormone, and luteinizing hormone, and estrogen.^{37,38}

Pregnancy-Related Complications

The endocannabinoid system is present in the uterine decidua, thus suggesting possible involvement in pregnancy complications such as miscarriage, pre-eclampsia, growth restriction and preterm labor.³⁵ Additionally, first trimester placentas express cannabinoid receptors, further implicating the role that alterations in the endocannabinoid system may play in pregnancy complications. Marijuana use during pregnancy has been shown to be associated with an increased fetal pulsatility index and resistance index of the uterine artery,³⁹ suggestive of increased placental resistance.⁴⁰ These findings may provide a partial explanation for intrauterine growth restriction.⁴¹

Fetal Growth and Birth Outcomes

Available data to this point do not reveal marijuana-associated fetal teratogenicity. Studies on the effects of prenatal maternal marijuana use on fetal growth and birth outcomes have yielded inconsistent results. A 2013 review of studies on prenatal marijuana exposure by Huizink⁴¹ specifically examined fetal growth, birth outcomes and early infant development using data from several sources including three prospective longitudinal studies: (1) the Ottawa Prenatal Prospective Study (OPPS), which began in 1978 and enrolled a predominantly middle-class, low-risk, Caucasian sample from Ottawa, Canada⁴²; (2) the Maternal Health Practice and Child Development Study (MHPCD), which started in 1982 and enrolled a high-risk, low socioeconomic status mixed Caucasian and African-American sample from Pittsburgh, PA⁴³ and (3) the Generation R study, which started in 2010 and recruited a multi-ethnic population-based cohort in Rotterdam, the Netherlands.⁴⁴ Of the three cohorts, only the Generation R study has examined fetal growth through ultrasound assessments several times during pregnancy.

Fetal Growth—A study using elective mid-gestation aborted fetuses (17 to 22 weeks) who were exposed to marijuana, tobacco, and alcohol demonstrated decreased weight and decreased foot length that was associated with marijuana exposure after controlling for other drug exposures.⁴⁵ No association was found between prenatal marijuana exposure and body length or head circumference after controlling for covariates.⁴⁵ Results from the Generation R study have shown: reduced fetal growth from the 2nd trimester onwards, particularly for mothers who used early marijuana during pregnancy or throughout the entire pregnancy.⁴⁶

Birth Outcomes—Results have differed between the three longitudinal cohorts described above with the OPPS reporting reduced gestational age but no differences in birth weight,⁴⁷ the MPHCD reporting reduced birth length after 1st trimester exposure and unexpectedly, increased birth weight after 3rd trimester exposure,⁴⁸ and Generation R reporting reduced birth weight.⁴⁶

Studies drawn from other sources yield conflicting results. A recent study by Hayatbakhsh et al. reported lower birth weight, by an average of 375 grams, lower gestational age, shorter body length and an increase in NICU admissions due to marijuana exposure after adjusting for tobacco, alcohol and other illicit drug exposures.⁴⁹ However, studies reporting no association between marijuana use and fetal growth include the Maternal Lifestyle Study,⁵⁰ a multicenter, prospective study of 8,600 women (which also included cocaine use)⁵¹ and the Avon Longitudinal Study of Pregnancy cohort of more than 12,000 pregnant women.⁵² A population-based study using data from the National Birth Defects Prevention Study also found no associations between marijuana use during pregnancy and mean birth weight, gestational age, low birth weight or preterm delivery.⁵³

Maternal Marijuana Use and Lactation

There is a paucity of data regarding the effects of maternal marijuana use on breastfeeding and infant outcomes. Small to moderate amounts of THC are secreted into breastmilk after maternal use with significant absorption by the infant. However, identification of side effects in the lactation-exposed infant are inconsistent,^{54,55} and no long-term outcome

studies are available. As noted in the previous section, studies of the endocannabinoid system from both the animal and human literature indicate there are neurobehavioral complications after marijuana exposure during pregnancy, raising the possibility of complications after exposure during lactation, as well. More detailed information is available in recent reviews by Rowe et al.⁵⁶ and Hill and Reed.²⁵ At the present time, the American Academy of Pediatrics recommends that women who are using street drugs, including marijuana, not breastfeed their infants.⁵⁷

DEVELOPMENTAL OUTCOMES OF PRENATAL MARIJUANA EXPOSURE: NEONATAL PERIOD TO EARLY ADULTHOOD

As outlined previously, several prospective, longitudinal cohort studies have evaluated the effects of prenatal marijuana exposure on offspring. However, the OPPS and the MHPCD are the only cohorts that have been followed into adolescence and early adulthood. Despite the demographic differences between these two cohorts, when the results overlap, they are remarkably consistent.

Neonatal Withdrawal and Neurobehavior

Withdrawal—Neonatal withdrawal from marijuana exposure has not been reported in any of the prospective, longitudinal studies.

Neurobehavior—Evidence of altered state regulation, manifested as increased startles and tremors, was identified in the OPPS sample during the first week of life⁵⁸ using the Neonatal Behavioral Assessment Scale (NBAS)⁵⁹ with similar results found again at 9 and 30 days⁶⁰ using the Prechtl⁶¹ neurologic examination. Poorer visual habituation and responses were also noted during the first week of life,⁵⁸ but these problems were not seen again at 9 and 30 days.⁶⁰ No effects were reported from the MHPCD on newborn behavior using the NBAS.⁴³ However, exposed newborns demonstrated altered sleep patterns with a decrease in quiet sleep and increased sleep motility suggesting increased activity in the noradrenergic system.⁶² Other newborn studies have demonstrated abnormal newborn cry,⁶³ also suggestive of increased arousal. Other investigators have found no abnormalities in infant behavior.^{64,65}

Prenatal Marijuana Exposure and Outcomes from Late Infancy to Young Adulthood

This section focuses on the areas of development where prenatal marijuana exposure appears to have a significant impact: executive function, attention, achievement, and behavior. Findings in other areas of development can be summarized as follows with details found in table 3.

Executive Function/Attention—Of importance, both cohorts have reported a negative effect of prenatal marijuana exposure on specific areas of cognition related to executive function at age 3 years,⁷¹ 4 years,⁶⁷ and 6 years.⁸¹ Findings in both cohorts include poorer scores on memory and verbal measures. At 6 years, Fried et al.⁸² reported a negative effect of prenatal marijuana exposure on the attentiveness of subjects using a vigilance task. This finding is consistent with that from the MHPCD at 6 years which showed increased

impulsivity on a vigilance task.⁸³ Children ages 9 to 12 in both the OPPS and the MHPCD showed poorer abstract/visual reasoning, impulse control, hypothesis testing, and visual problem solving.^{84–86} At age 10, marijuana-exposed youth in the MHPCD were more likely to exhibit hyperactivity, impulsivity, and inattention, according to maternal report.⁸⁷ Finally, two studies from the OPPS when subjects were 13 to 16 years old documented continued problems with executive function and attention. Adolescents with prenatal marijuana exposure demonstrated decreased attentional stability as evidenced by a decreasing consistency in reaction time as the test progressed and by an increase in errors of omission.⁸⁸ The exposed adolescents also had poorer scores on two measures indicative of problems with visual memory, analysis, and integration.⁶⁹ Several additional studies from the Ottawa sample have used fMRI to evaluate the subjects between 18 to 22 years. While performing a response inhibition task, changes in neural activity were noted on fMRI when compared to the non-exposed subjects.⁸⁹ Although the exposed subjects committed more errors of commission, all were able to finish the task with 85% accuracy or more. While performing a visuospatial working memory task, the exposed subjects showed changes in neural activity on fMRI when compared to the nonexposed subjects although there was no group differences in performance.^{90,91}

Academic Achievement—Using tests, studies from the OPPS at ages 6 to 9 years⁹² and 13 to 16 years⁹³ showed no effect of prenatal marijuana exposure on standardized academic achievement test scores. This is in contrast to the findings from the MHPCD. Again, using standardized achievement tests, prenatally exposed children had lower reading, spelling and reading comprehension scores at age 10.⁹⁴ Similar results were found at age 14 with lower global achievement and reading scores in the prenatally exposed adolescents.⁹⁵

Behavior Problems—Parental reports for subjects in the OPPS showed increased conduct disorders in children from 6 to 9 years old.⁹² Parental and teacher reports obtained at age 10 for subjects in the MHPCD revealed increased delinquency and externalizing behaviors.⁹⁶ Also, an increase in self-reported depressive symptoms was identified at age 10 for exposed subjects in the MHPCD.⁹⁷ At age 14, the age of onset and frequency of the youth's marijuana use was predicted by their prenatal exposure.⁹⁸ This finding was also seen in 16- to 21-year-olds from the OPPS.⁹⁹ In this study, subjects who were prenatally exposed to marijuana were at greater risk for initiating cigarette smoking and daily use and for initiating marijuana use.

SUMMARY

Evidence about the effects of marijuana use during pregnancy- and fetal-related complications and child development is inconclusive. Data from preclinical studies is suggestive of negative outcomes based on disruptive effects on the endocannabinoid system. The results from longitudinal prospective studies that started in the late 1970s and early 1980s indicate subtle effects on attention, executive functions and behavior, particularly as marijuana-exposed youth develop into adolescence and early adulthood. Given that today's marijuana is 6- to 7-times more potent and more likely to be consumed in greater average amounts by younger users, continued surveillance is warranted and may reveal more significant short- and long-term harms. The practice of medicine for physicians who care for

marijuana-using pregnant women is being shaped by shifting societal pressures. Increasingly, marijuana is being thought of as “medicine” by the general public as evidenced by “medical” marijuana laws. Pro-marijuana advocacy efforts may lead to perceptions about marijuana as being relatively “safe” and result in increased use by several groups, including pregnant women. At the same time, pregnant women who use illicit drugs and controlled substances such as prescription opioid analgesics are being criminalized and charged with child abuse and other felonies – despite efforts from scientists and medical professionals. Nationwide educational efforts are imperative in order to assure women are not misled into believing that marijuana use in pregnancy is without possible danger to the developing fetus. Further research is critical to ascertain the specific risks to the developing fetus both in utero and beyond.

References

1. ProCon.org. [Accessed May 30, 2014] 22 legal medical marijuana states and dc: laws, fees, and possession limits - I Summary chart. Available at: <http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881>
2. ProCon.org. [Accessed May 30, 2014] 4 states with pending legislation to legalize medical marijuana (as of May 29, 2014). Available at: <http://medicalmarijuana.procon.org/view.resource.php?resourceID=002481>
3. Johnston LD, Miech RA, Bachman JG, et al. Monitoring the Future national survey results on drug use: 1975–2013: overview, key findings on adolescent drug use. Ann Arbor. 2014
4. Substance Abuse And Mental Health Services Administration. NSDUH series H-46, HHS publication no. (SMA) 13-4798. Rockville, MD: 2013. Results from the 2012 National Survey on Drug Use and Health: summary of national findings.
5. Substance Abuse and Mental Health Services Administration Office of Applied Studies. The NSDUH report: substance use among women during pregnancy and following childbirth. Rockville, MD: 2009.
6. Van Gelder MMHJ, Reefhuis J, Caton AR, et al. Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study. Drug Alcohol Depend. 2010; 109(1–3):243–7. [PubMed: 20171023]
7. Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology part one of two. J Pain Palliat Care Pharmacother. 2009; 23(1):120–40. [PubMed: 19492213]
8. Cerdá M, Wall M, Keyes KM, et al. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012; 120(1–3):22–7. [PubMed: 22099393]
9. Pacula RL, Sevigny EL. Marijuana liberalization policies: why we can’t learn much from policy still in motion. J Policy Anal Manage. 2014; 33(1):212–21. [PubMed: 24358530]
10. Anderson, DM.; Hansen, B.; Rees, DI. Medical marijuana laws and teen marijuana use, iza discussion papers, no 6592 [rev]. Bonn, Germany: 2012.
11. Sevigny EL, Pacula RL, Heaton P. The effects of medical marijuana laws on potency. Int J Drug Policy. 2014; 25(2):308–19. [PubMed: 24502887]
12. Beatty JR, Svikis DS, Ondersma SJ. Prevalence and perceived financial costs of marijuana versus tobacco use among urban low-income pregnant women. J Addict Res Ther. 2013; 3(4):1–12.
13. McLaren J, Swift W, Dillon P, et al. Cannabis potency and contamination: a review of the literature. Addiction. 2008; 103(7):1100–9. [PubMed: 18494838]
14. Sevigny EL. Is today’s marijuana more potent simply because it’s fresher? Drug Test Anal. 2013; 5(1):62–7. [PubMed: 23169764]
15. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of ⁹-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010; 55(5):1209–17. [PubMed: 20487147]

16. Mariani JJ, Brooks D, Haney M, et al. Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes. *Drug Alcohol Depend.* 2011; 113(2–3):249–51. [PubMed: 20863627]
17. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 422: at-risk drinking and illicit drug use: ethical issues in obstetric and gynecologic practice. *Obstet Gynecol.* 2008; 2008(422):1449–60.
18. American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women. ACOG Committee Opinion No. 473: substance abuse reporting and pregnancy: the role of the obstetrician-gynecologist. *Obstet Gynecol.* 2011; 117(1):200–1. [PubMed: 21173672]
19. American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women and the American Society of Addiction Medicine. . ACOG committee Opinion No. 524: opioid abuse, dependence, and addition in pregnancy. *Obstet Anesth Dig.* 2012; 33(2):79–80.
20. American Society of Addiction Medicine. Public policy statement on women, alcohol and other drugs, and pregnancy. 2011.
21. Kennedy C, Finkelstein N, Hutchins E, et al. Improving screening for alcohol use during pregnancy: the massachusetts asap program. *Matern Child Health J.* 2004; 8(3):137–47. [PubMed: 15503394]
22. Institute for Health and Recovery. Integrated 5 P's screening tool. Watertown, MA: Massachusetts Health Quality Partners;
23. Behnke M, Smith VC. Prenatal substance abuse: short- and long-term effects on the exposed fetus. *Pediatrics.* 2013; 131(3):e1009–24. [PubMed: 23439891]
24. Guttmacher Institute. State policies in brief: substance abuse during pregnancy (as of may 2014). New York: New York: 2014.
25. Hill M, Reed K. Pregnancy, breast-feeding, and marijuana: a review article. *Ostet Gynecol Surv.* 2013; 68(10):710–718.
26. Jaques SC, Kingsbury a, Henshcke P, et al. Cannabis, the pregnant woman and her child: weeding out the myths. *J Perinatol.* 2014; (November 2013):1–8. [PubMed: 23970208]
27. Egerton A, Allison C, Brett RR, et al. Cannabinoids and prefrontal cortical function: insights from preclinical studies. *Neurosci Biobehav Rev.* 2006; 30(5):680–95. [PubMed: 16574226]
28. Trezza V, Cuomo V, Vanderschuren LJMJ. Cannabis and the developing brain: insights from behavior. *Eur J Pharmacol.* 2008; 585(2–3):441–52. [PubMed: 18413273]
29. Jutras-Aswad D, DiNieri JAJ, Harkany T, et al. Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. *Eur Arch Psychiatry Clin Neurosci.* 2009; 259(7):395–412. [PubMed: 19568685]
30. Campolongo P, Trezza V, Palmery M, et al. Developmental exposure to cannabinoids causes subtle and enduring neurofunctional alterations. *Int Rev Neurobiol.* 2009; 85:117–33. [PubMed: 19607965]
31. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. *J Am Chem Soc.* 1964; 86(8):1646–1647.
32. Devane W, Dysarz F, Johnson M, et al. Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol.* 1988; 34(5):605–613. [PubMed: 2848184]
33. Rawitch A, Schultz G, Ebner K, et al. Competition of delta 9-tetrahydrocannabinol with estrogen in rat uterine estrogen receptor binding. *Science (80-).* 1977; 197(4309):1189–1191.
34. Sun X, Xie H, Yang J, et al. Endocannabinoid signaling directs differentiation of trophoblast cell lineages and placentation. *Proc Natl Acad Sci U S A.* 2010; 107(39):16887–92. [PubMed: 20837524]
35. Fonseca BM, Correia-da-Silva G, Almada M, et al. The endocannabinoid system in the postimplantation period: a role during decidualization and placentation. *Int J Endocrinol.* 2013:Article ID: 510540.
36. Fronczak CM, Kim ED, Barqawi AB. The insults of illicit drug use on male fertility. *J Androl.* 2012; 33(4):515–28. [PubMed: 21799144]
37. Lee SY, Oh SM, Chung KH. Estrogenic effects of marijuana smoke condensate and cannabinoid compounds. *Toxicol Appl Pharmacol.* 2006; 214(3):270–8. [PubMed: 16499939]

38. Brown TT, Dobs AS. Endocrine effects of marijuana. *J Clin Pharmacol.* 2002; 42(S1):90S–96S. [PubMed: 12412841]
39. El Marroun H, Tiemeier H, Steegers EaP, et al. A prospective study on intrauterine cannabis exposure and fetal blood flow. *Early Hum Dev.* 2010; 86(4):231–6. [PubMed: 20451334]
40. Boito S, Struijk PC, Ursem NTC, et al. Umbilical venous volume flow in the normally developing and growth-restricted human fetus. *Ultrasound Obstet Gynecol.* 2002; 19(4):344–9. [PubMed: 11952962]
41. Huizink A. Prenatal cannabis exposure and infant outcomes: overview of studies. *Prog Neuropsychopharmacol Biol Psychiatry.* 2013; 52:45–52. [PubMed: 24075896]
42. Fried PA. The Ottawa Prenatal Prospective Study (OPPS): methodological issues and findings — it’s easy to throw the baby out with the bath water. *Life Sci.* 1995; 56(23–24):2159–2168. [PubMed: 7539879]
43. Richardson GA, Day NL, Taylor PM. The effect of prenatal alcohol, marijuana, and tobacco exposure on neonatal behavior. *Infant Behav Dev.* 1989; 12(2):199–209.
44. Jaddoe VWV, Mackenbach JP, Moll HA, et al. The Generation R study: design and cohort profile. *Eur J Epidemiol.* 2006; 21(6):475–84. [PubMed: 16826450]
45. Hurd YL, Wang X, Anderson V, et al. Marijuana impairs growth in mid-gestation fetuses. *Neurotoxicol Teratol.* 2005; 27(2):221–9. [PubMed: 15734273]
46. El Marroun H, Tiemeier H, Steegers EAP, et al. Intrauterine cannabis exposure affects fetal growth trajectories: the generation r study. *J Am Acad Child Adolesc Psychiatry.* 2009; 48(12):1173–81. [PubMed: 19858757]
47. Fried PA, O’Connell CM. A comparison of the effects of prenatal exposure to tobacco, alcohol, cannabis and caffeine on birth size and subsequent growth. *Neurotoxicol Teratol.* 1987; 9(2):79–85. [PubMed: 3657756]
48. Day N, Sambamoorthi U, Taylor P, et al. Prenatal marijuana use and neonatal outcome. *Neurotoxicol Teratol.* 1991; 13(3):329–334. [PubMed: 1886543]
49. Hayatbakhsh MR, Flenady VJ, Gibbons KS, et al. Birth outcomes associated with cannabis use before and during pregnancy. *Pediatr Res.* 2012; 71(2):215–9. [PubMed: 22258135]
50. Lester BM, Tronick EZ, LaGasse L, et al. The Maternal Lifestyle Study: effects of substance exposure during pregnancy on neurodevelopmental outcome in 1-month-old infants. *Pediatrics.* 2002; 110(6):1182–1192. [PubMed: 12456917]
51. Bada HS, Das A, Bauer CR, et al. Low birth weight and preterm births: etiologic fraction attributable to prenatal drug exposure. *J Perinatol.* 2005; 25(10):631–7. [PubMed: 16107872]
52. Fergusson DM, Horwood LJ, Northstone K. Maternal use of cannabis and pregnancy outcome. *BJOG.* 2002; 109(1):21–7. [PubMed: 11843371]
53. Van Gelder MMHJ, Reefhuis J, Caton AR, et al. Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study. *Drug Alcohol Depend.* 2010; 109(1–3):243–7. [PubMed: 20171023]
54. Tennes K, Avitable N, Blackard C, et al. Marijuana: prenatal and postnatal exposure in the human. *NIDA Res Monogr.* 1985; 59:48–60. [PubMed: 3929132]
55. Astley SJ, Little RE. Maternal marijuana use during lactation and infant development at one year. *Neurotoxicol Teratol.* 1990; 12(2):161–168. [PubMed: 2333069]
56. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. *Pediatr Clin North Am.* 2013; 60(1):275–94. [PubMed: 23178070]
57. American Academy of Pediatrics Section on Breastfeeding. Breastfeeding and the use of human milk. *Pediatrics.* 2012; 129(3):e827–41. [PubMed: 22371471]
58. Fried PA, Makin JE. Neonatal behavioural correlates of prenatal exposure to marihuana, cigarettes and alcohol in a low risk population. *Neurotoxicol Teratol.* 1987; 9(1):1–7. [PubMed: 3627073]
59. Brazelton, T. Clinics in. Philadelphia: JB Lippincott; 1973. Neonatal Behavioral Assessment Scale.
60. Fried P, Watkinson B, Dillon F, et al. Neonatal neurologic status in a low-risk population after prenatal exposure to cigarettes, marijuana, and alcohol. *J Dev Behav Pediatr.* 1987; 8(6):318–326. [PubMed: 3429670]

61. Prechtl, HFR. The neurological examination of the full term newborn infant: a manual for clinical use. Cambridge University Press; 1977.
62. Scher MS, Richardson GA, Coble PA, et al. The effects of prenatal alcohol and marijuana exposure: disturbances in neonatal sleep cycling and arousal. *Pediatr Res*. 1988; 24(1):101–5. [PubMed: 3412843]
63. Lester BM, Dreher M. Effects of marijuana use during pregnancy on newborn cry. *Child Dev*. 1989; 60(4):765–71. [PubMed: 2758874]
64. Hayes JS, Dreher MC, Nugent JK. Newborn outcomes with maternal marijuana use in jamaican women. *Pediatr Nurs*. 14(2):107–10. [PubMed: 3353135]
65. Dreher MC, Nugent K, Hudgins R. Prenatal marijuana exposure and neonatal outcomes in jamaica: an ethnographic study. *Pediatrics*. 1994; 93(2):254–60. [PubMed: 8121737]
66. Fried PA, Watkinson B. 12- and 24-month neurobehavioural follow-up of children prenatally exposed to marijuana, cigarettes and alcohol. *Neurotoxicol Teratol*. 1988; 10(4):305–313. [PubMed: 3226373]
67. Fried P, Watkinson B. 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes and alcohol. *J Dev Behav Pediatr*. 1990; 11(2):49–58. [PubMed: 2324288]
68. Fried P, O'Connell C, Watkinson B. 60- and 72-month follow-up of children prenatally exposed to marijuana, cigarettes and alcohol: cognitive and language assessment. *J Dev Behav Pediatr*. 1992; 13:383–391. [PubMed: 1469105]
69. Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marijuana. *Neurotoxicol Teratol*. 2003; 25(4):427–436. [PubMed: 12798960]
70. Richardson GA, Day NL, Goldschmidt L. Prenatal alcohol, marijuana, and tobacco use: infant mental and motor development. *Neurotoxicol Teratol*. 1995; 17(4):479–487. [PubMed: 7565494]
71. Day NL, Richardson GA, Goldschmidt L, et al. Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. *Neurotoxicol Teratol*. 1994; 16(2):169–175. [PubMed: 8052191]
72. Dahl RE. A longitudinal study of prenatal marijuana use. *Arch Pediatr Adolesc Med*. 1995; 149(2):145. [PubMed: 7849875]
73. Fried PA, Watkinson B, Siegel LS. Reading and language in 9- to 12-year olds prenatally exposed to cigarettes and marijuana. *Neurotoxicol Teratol*. 1997; 19(3):171–83. [PubMed: 9200137]
74. Chandler LS, Richardson GA, Gallagher JD, et al. Prenatal exposure to alcohol and marijuana: effects on motor development of preschool children. *Alcohol Clin Exp Res*. 1996; 20(3):455–461. [PubMed: 8727237]
75. Willford JA, Chandler LS, Goldschmidt L, et al. Effects of prenatal tobacco, alcohol and marijuana exposure on processing speed, visual-motor coordination, and interhemispheric transfer. *Neurotoxicol Teratol*. 2010; 32(6):580–8. [PubMed: 20600845]
76. Fried PA, Watkinson B, Gray R. Growth from birth to early adolescence in offspring prenatally exposed to cigarettes and marijuana. *Neurotoxicol Teratol*. 1999; 21(5):513–525. [PubMed: 10492386]
77. Fried PA, James DS, Watkinson B. Growth and pubertal milestones during adolescence in offspring prenatally exposed to cigarettes and marijuana. *Neurotoxicol Teratol*. 2001; 23(5):431–436. [PubMed: 11711245]
78. Day N, Cornelius M, Goldschmidt L, et al. The effects of prenatal tobacco and marijuana use on offspring growth from birth through 3 years of age. *Neurotoxicol Teratol*. 1992; 14(6):407–414. [PubMed: 1488035]
79. Day NL, Richardson GA, Geva D, et al. Alcohol, marijuana, and tobacco: effects of prenatal exposure on offspring growth and morphology at age six. *Alcohol Clin Exp Res*. 1994; 18(4):786–794. [PubMed: 7526725]
80. Cornelius MD, Goldschmidt L, Day NL, et al. Alcohol, tobacco and marijuana use among pregnant teenagers: 6-year follow-up of offspring growth effects. *Neurotoxicol Teratol*. 2002; 24(6):703–710. [PubMed: 12460652]

81. Goldschmidt L, Richardson GA, Willford J, et al. Prenatal marijuana exposure and intelligence test performance at age 6. *J Am Acad Child Adolesc Psychiatry*. 2008; 47(3):254–63. [PubMed: 18216735]
82. Fried PA, Watkinson B, Gray R. A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marijuana, cigarettes, and alcohol. *Neurotoxicol Teratol*. 1992; 14(5):299–311. [PubMed: 1454038]
83. Leech SL, Richardson GA, Goldschmidt L, et al. Prenatal substance exposure: effects on attention and impulsivity of 6-year-olds. *Neurotoxicol Teratol*. 1999; 21(2):109–18. [PubMed: 10192271]
84. Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning 9- to 12-year olds prenatally exposed to cigarettes and marijuana. *Neurotoxicol Teratol*. 1998; 20(3):293–306. [PubMed: 9638687]
85. Fried PA, Watkinson B. Visuo-perceptual functioning differs in 9- to 12-year olds prenatally exposed to cigarettes and marijuana. *Neurotoxicol Teratol*. 2000; 22(1):11–20. [PubMed: 10642110]
86. Richardson G. Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. *Neurotoxicol Teratol*. 2002; 24(3):309–320. [PubMed: 12009486]
87. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. *Neurotoxicol Teratol*. 2000; 22(3):325–36. [PubMed: 10840176]
88. Fried P, Watkinson B. Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marijuana. *Neurotoxicol Teratol*. 2001; 23(5):421–430. [PubMed: 11711244]
89. Smith AM, Fried PA, Hogan MJ, et al. Effects of prenatal marijuana on response inhibition: an fMRI study of young adults. *Neurotoxicol Teratol*. 2004; 26(4):533–42. [PubMed: 15203175]
90. Smith AM, Fried PA, Hogan MJ, et al. Effects of prenatal marijuana on visuospatial working memory: an fMRI study in young adults. *Neurotoxicol Teratol*. 2006; 28(2):286–95. [PubMed: 16473495]
91. Smith AM, Longo CA, Fried PA, et al. Effects of marijuana on visuospatial working memory: an fMRI study in young adults. *Psychopharmacology (Berl)*. 2010; 210(3):429–438. [PubMed: 20401748]
92. O'Connell CM, Fried PA. Prenatal exposure to cannabis: a preliminary report of postnatal consequences in school-age children. *Neurotoxicol Teratol*. 1991; 13(6):631–639. [PubMed: 1779951]
93. Fried PA. Behavioral outcomes in preschool and school-age children exposed prenatally to marijuana: a review and speculative interpretation. *NIDA Res Monogr*. 1996; 164:242–60. [PubMed: 8809875]
94. Goldschmidt L, Richardson GA, Cornelius MD, et al. Prenatal marijuana and alcohol exposure and academic achievement at age 10. *Neurotoxicol Teratol*. 2004; 26(4):521–32. [PubMed: 15203174]
95. Goldschmidt L, Richardson GA, Willford JA, et al. School achievement in 14-year-old youths prenatally exposed to marijuana. *Neurotoxicol Teratol*. 2012; 34(1):161–7. [PubMed: 21884785]
96. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. *Neurotoxicol Teratol*. 2000; 22(3):325–36. [PubMed: 10840176]
97. Gray KA, Day NL, Leech S, et al. Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. *Neurotoxicol Teratol*. 2005; 27(3):439–48. [PubMed: 15869861]
98. Day NL, Goldschmidt L, Thomas CA. Prenatal marijuana exposure contributes to the prediction of marijuana use at age 14. *Addiction*. 2006; 101(9):1313–22. [PubMed: 16911731]
99. Porath AJ, Fried PA. Effects of prenatal cigarette and marijuana exposure on drug use among offspring. *Neurotoxicol Teratol*. 2005; 27(2):267–77. [PubMed: 15734278]

KEY POINTS

- Pro-marijuana advocacy may result in an increase in the prevalence of marijuana use during pregnancy, particularly among young adolescents who already report the highest use among all pregnant women.
- Today's marijuana is 6 to 7 times more potent than marijuana from the 1970s and average marijuana consumption, particularly among adolescents and young adults, may be higher due to growing popularity of blunts compared to joints.
- Adverse fetal outcomes related to marijuana use during pregnancy remain unclear based on the currently available research. However, prenatal use has been associated with infertility, placental complications of pregnancy, and fetal growth restriction.
- Long-term effects of prenatal marijuana use on exposed offspring include poorer executive functioning skills and attention, increased conduct and behavior problems, and poorer school achievement.
- Intersecting political forces and medical issues mandate that physicians be knowledgeable marijuana use by their patients and be prepared to counsel their patients about the effects of prenatal marijuana use on fertility, pregnancy, and the exposed offspring.

Table 1
 Percentage Substance Use in the Past Month Among Women Ages 15 to 44 by Pregnancy Status, Age Group and Trimester

Drug	Total Sample	Pregnancy Status		Pregnancy Age Group			Trimester Use		
		Non-Pregnant Women	Pregnant Women	15-17	18-25	26-44	First	Second	Third
ILLICIT DRUGS ¹	10.5	10.7	5.9	18.3	9.0	3.4	11.6	4.0	2.3
Marijuana and Hashish	8.2	8.3	5.2	16.5	7.5	3.3	10.7	2.8	2.3
CIGARETTES	24.2	24.6	15.9	*	20.9	12.5	23.2	13.6	11.1
ALCOHOL	53.8	55.5	8.5	13.4	7.3	9.0	17.9	4.2	3.7

¹ Illicit Drugs include marijuana/hashish, cocaine (including crack), heroin, hallucinogens, inhalants, or prescription-type psychotherapeutics used nonmedically.

* Low precision; no estimate reported.

Data from SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011-2012 (Miscellaneous Tables 6.71B, 6.73B, 6.74B, 6.75B and 6.76B).

Table 2

State Policies on Substance Abuse During Pregnancy

STATE	SUBSTANCE ABUSE DURING PREGNANCY CONSIDERED:		WHEN ABUSE SUSPECTED, STATE REQUIRES:		DRUG TREATMENT FOR PREGNANT WOMEN		
	Child Abuse	Grounds for Civil Commitment	Reporting	Testing	Targeted Program Created	Pregnant Women Given Priority Access in General Programs	Pregnant Women Protected from Discrimination in Publicly Funded Programs
Alaska			X				
Arizona			X			X	
Arkansas	X				X		
California					X		
Colorado	X				X		
Connecticut					X		
Florida	X				X		
Georgia						X	
Illinois	X		X		X		
Indiana	X						
Iowa	X		X	X			X
Kansas						X	X
Kentucky				X	X		
Louisiana	X		X		X		
Maryland			X		X	X	
Massachusetts			X				
Michigan			X				
Minnesota	X	X	X	X	X		
Missouri						X ¹²	X
Montana			X				
Nebraska					X [†]		
Nevada	X						
New York							

STATE	SUBSTANCE ABUSE DURING PREGNANCY CONSIDERED:		WHEN ABUSE SUSPECTED, STATE REQUIRES:		DRUG TREATMENT FOR PREGNANT WOMEN		
	Child Abuse	Grounds for Civil Commitment	Reporting	Testing	Targeted Program Created	Pregnant Women Given Priority Access in General Programs	Pregnant Women Protected from Discrimination in Publicly Funded Programs
North Carolina							
North Dakota			X	X			
Ohio							
Oklahoma	X		X			X	X
Oregon					X [†]		
Pennsylvania					X		
Rhode Island	X		X				
South Carolina	X*						
South Dakota	X	X					
Tennessee	X					X	
Texas	X					X	
Utah			X			X	
Virginia	X		X		X		
Washington					X		
Wisconsin	X	X				X	
TOTAL	17	3	15	4	18	10	4

* The South Carolina Supreme Court held that a viable fetus is a "person" under the state's criminal child-endangerment statute and that "maternal acts endangering or likely to endanger the life, comfort, or health of a viable fetus" constitute criminal child abuse.

[†] Applies only to women and newborns eligible for Medicaid.

[‡] Establishes requirements for health care providers to encourage and facilitate drug counseling.

[§] Priority applies to pregnant women referred for treatment.

The Guttmacher Institute, State Policies in Brief: Substance Abuse During Pregnancy, May 1, 2014.

Table 3

Finding in areas of development in prenatal marijuana exposure.

1	Minimal, inconsistent effect on general cognition ⁶⁶⁻⁷¹
2	Altered sleep patterns ⁷²
3	No effect on language ^{66-68,73}
4	Minimal effect on motor development ^{55,66,70,74,75}
5	Minimal effects on growth and pubertal development ^{47,76-80}
